VETERINARY MEDICINE BUSINESS
Woogene B&G is well known for the specialty in innovation which recognized to have the excellent techniques and superior products in the Animal Health business. In the beginning, our raw materials were supplied exclusively by well renowned multinational companies. As we adopt their techniques and their high standards we come up with an idea to ensure the safety and maintain the high quality standard that we provide to our customers.
In order to provide great service to our customers, WooGene B&G offers wide range of support for our continuous partnership. We want to provide knowledge about productive management, continuous innovations and support to eliminate diseases. We are trained to assessed diseases in scientific approach by investigating farm history and practice quarantine and proper hygiene. We provide services as a support to our clients and its stakeholders.
MICROBIAL TECHNOLOGY BUSINESS
Woogene B&G has been steadily developing microbial culture and fermentation technology to produce eco-friendly products since the 1980s because we recognized the seriousness of resistance development due to the misuse of antibiotics. The strains we secured through long-term research have been registered as international patent strains, and are used to produce pharmaceuticals and feed additives. Plus, we produce products which are helpful for eco-friendly livestock by developing odor removers and environmental improvement agents. All of the excellent microbial is sold as finished products and raw materials in both domestic market and overseas market. Especially export rates are increasing.
VACCINES BUSINESS
Woogene B&G have not been entirely satisfied with the business result expanded our business to the animal vaccine industry. In 2017, PED-M (inactivated porcine epidemic diarrhea virus) vaccine was released and due to higher efficiency result, vaccine bussiness in domestic market starts to grow. And in 2019, we got the registration from the government of Kazakhstan. Thus, export to the Eastern European countries and CIS are available. Our research focus on expanding various additional vaccines such as CFS, PRRS, PCV2 and etc.
